Is Wilhelmina International, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Wilhelmina International, Inc. moved from very expensive to attractive, indicating a significant shift in its perceived value. The company is currently considered undervalued based on its metrics. Key ratios include a P/E Ratio of 21, a Price to Book Value of 0.83, and an EV to EBITDA of 8.84, which suggest that the stock is trading at a discount relative to its earnings and book value.
In comparison to peers, Wilhelmina International, Inc. has a more favorable P/E ratio than Coya Therapeutics, Inc. at -5.23 and a better EV to EBITDA ratio than Team, Inc. at 9.80. This positions Wilhelmina as an attractive investment within its industry. Although specific return data is not available, the overall valuation narrative suggests that the stock may have underperformed against the S&P 500, reinforcing the notion that it is currently undervalued.